PDF(Pubmed)
Abstract：
UNASSIGNED: Accumulating studies suggested that major depressive disorder (MDD) was closely related to metabolic syndrome (MetS). Important endogenous regulators fibroblast growth factors (FGFs) 19 and 21 were also reported to participate in psychiatric disorders. This study aimed to investigate the role of FGF19 and FGF21 in MDD and to explore the possible pathogenic mechanism of metabolic and cognitive dysregulation in depression.
UNASSIGNED: A total of 59 MDD patients and 55 healthy control participants were recruited. The serum levels of FGF19 and FGF21 and lipid profiles were measured by means of enzymatic methods. Cognitive function was measured by repeatable battery for the assessment of neuropsychological status (RBANS) scores. The gene expression of PGC-1α and FNDC5 was determined by quantitative polymerase chain reaction (PCR).
UNASSIGNED: We found that plasma FGF19 and FGF21 levels were significantly decreased in patients with MDD. Meanwhile, triglyceride (TG) was significantly elevated and PGC-1α was significantly downregulated in MDD patients. Correlation analyses showed negative associations between TG and FGF19 levels. As for cognitive performance, both FGF19 and FGF21 levels were positively correlated with immediate memory. However, FGF19 levels were negatively correlated with language, and FGF21 levels were also negatively correlated with attention and delayed memory. Additionally, negative associations were found between FGF19 levels and PGC-1α. FGF21 levels were positively associated with PGC-1α and negatively associated with FNDC5.
UNASSIGNED: This study elucidated the role of FGF19 and FGF21 in MDD. MDD patients were confirmed to have metabolic and cognitive dysregulation, and this abnormality was linked to the decreased concentrations of FGF19 and FGF21 through the PGC-1α/FNDC5 pathway. Our results showed that the alterations of FGF19 and FGF21 levels may be a common pathogenic mechanism of metabolic and cognitive disturbances in patients with MDD.
UNASSIGNED: A total of 59 MDD patients and 55 healthy control participants were recruited. The serum levels of FGF19 and FGF21 and lipid profiles were measured by means of enzymatic methods. Cognitive function was measured by repeatable battery for the assessment of neuropsychological status (RBANS) scores. The gene expression of PGC-1α and FNDC5 was determined by quantitative polymerase chain reaction (PCR).
UNASSIGNED: We found that plasma FGF19 and FGF21 levels were significantly decreased in patients with MDD. Meanwhile, triglyceride (TG) was significantly elevated and PGC-1α was significantly downregulated in MDD patients. Correlation analyses showed negative associations between TG and FGF19 levels. As for cognitive performance, both FGF19 and FGF21 levels were positively correlated with immediate memory. However, FGF19 levels were negatively correlated with language, and FGF21 levels were also negatively correlated with attention and delayed memory. Additionally, negative associations were found between FGF19 levels and PGC-1α. FGF21 levels were positively associated with PGC-1α and negatively associated with FNDC5.
UNASSIGNED: This study elucidated the role of FGF19 and FGF21 in MDD. MDD patients were confirmed to have metabolic and cognitive dysregulation, and this abnormality was linked to the decreased concentrations of FGF19 and FGF21 through the PGC-1α/FNDC5 pathway. Our results showed that the alterations of FGF19 and FGF21 levels may be a common pathogenic mechanism of metabolic and cognitive disturbances in patients with MDD.
摘要：
■大量研究表明，重度抑郁症（MDD）与代谢综合征（MetS）密切相关。据报道，重要的内源性调节因子成纤维细胞生长因子（FGFs）19和21也参与了精神疾病。本研究旨在研究FGF19和FGF21在MDD中的作用，探讨代谢和认知功能失调在抑郁症中的可能致病机制。
■共招募了59名MDD患者和55名健康对照参与者。通过酶法测量FGF19和FGF21的血清水平和脂质谱。通过可重复电池测量认知功能，以评估神经心理学状态（RBANS）评分。通过定量聚合酶链反应（PCR）确定PGC-1α和FNDC5的基因表达。
■我们发现MDD患者血浆FGF19和FGF21水平显着降低。同时,MDD患者甘油三酯（TG）显著升高，PGC-1α显著下调。相关分析显示TG和FGF19水平呈负相关。至于认知表现，FGF19和FGF21水平均与即时记忆呈正相关。然而,FGF19水平与语言呈负相关，FGF21水平也与注意力和延迟记忆呈负相关。此外,FGF19水平与PGC-1α呈负相关。FGF21水平与PGC-1α呈正相关，与FNDC5呈负相关。
■本研究阐明了FGF19和FGF21在MDD中的作用。MDD患者被证实有代谢和认知失调，这种异常与通过PGC-1α/FNDC5途径降低的FGF19和FGF21浓度有关。我们的结果表明，FGF19和FGF21水平的改变可能是MDD患者代谢和认知障碍的常见致病机制。
■共招募了59名MDD患者和55名健康对照参与者。通过酶法测量FGF19和FGF21的血清水平和脂质谱。通过可重复电池测量认知功能，以评估神经心理学状态（RBANS）评分。通过定量聚合酶链反应（PCR）确定PGC-1α和FNDC5的基因表达。
■我们发现MDD患者血浆FGF19和FGF21水平显着降低。同时,MDD患者甘油三酯（TG）显著升高，PGC-1α显著下调。相关分析显示TG和FGF19水平呈负相关。至于认知表现，FGF19和FGF21水平均与即时记忆呈正相关。然而,FGF19水平与语言呈负相关，FGF21水平也与注意力和延迟记忆呈负相关。此外,FGF19水平与PGC-1α呈负相关。FGF21水平与PGC-1α呈正相关，与FNDC5呈负相关。
■本研究阐明了FGF19和FGF21在MDD中的作用。MDD患者被证实有代谢和认知失调，这种异常与通过PGC-1α/FNDC5途径降低的FGF19和FGF21浓度有关。我们的结果表明，FGF19和FGF21水平的改变可能是MDD患者代谢和认知障碍的常见致病机制。
